Manoj Raghavan
@HaemOnc
Followers
831
Following
1K
Media
38
Statuses
725
Consultant & senior lecturer in haematology oncology, myeloid disease and diagnostic genetics/genomics. Co-chief investigator on @Repair_MDS trial.
University of Birmingham, UK
Joined April 2009
RT @BloodPortfolio: ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance. https://t….
0
8
0
RT @LabWaggoner: Review: CAR-T cell therapy for cancer: current challenges and future directions.@Menendez_Lab @Ine….
0
98
0
Congratulations Andy!.
Thanks to @unibirmingham for nominating me for, and being fortunate to win on behalf of @beggs_lab the Josiah Mason Founders Award for Academic Advancement. Video of our work:.
0
0
0
Delighted to announce that our paper showing the generation of iPSc from a MDS patient & how CEBPA drives disease progression is finally out in Nature Comms! A big thanks to everybody involved & the great collaborators that have made it possible!.
0
1
1
RT @DrEmmaSearle: Proud to finally get this data out. A negative study but very important to make sure our negative studies are published a….
0
3
0
RT @emmamgroarke: Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now publish….
0
11
0
RT @BloodAdvances: This nationwide study shows that major bleeding and thromboembolic events are more frequent in MF than previously descri….
0
2
0
RT @LeukemiaJnl: Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia https:….
nature.com
Leukemia - Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
0
6
0
0
0
0
RT @LeukemiaJnl: Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Confere….
nature.com
Leukemia - Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)
0
26
0
RT @TalhaBadarMD: Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor f….
0
6
0
RT @BloodPortfolio: Despite increased use of next-generation sequencing, newly diagnosed patients considering intensive chemotherapy still….
0
4
0
RT @BloodPortfolio: Almost half of patients with acute myeloid leukemia are aged ≥70 years at diagnosis. #BloodSpot….
0
9
0
RT @TalhaBadarMD: Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML | Journal of Clinical Onc….
0
24
0
RT @beth_psaila: Exciting times for mutCALR MPNs - lovely data from the ET cohort presented in late breaking abstract at @EHA_Hematology. R….
0
13
0
RT @TalhaBadarMD: #EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts. 1. Ve….
0
27
0
RT @NicoGagelmann: Macrophage Makeover: Bexmarilimab Boosts Azacitidine in High-Risk MDS and AML. Summary:.In a phase 1 trial, the Clever-1….
0
3
0
RT @NicoGagelmann: Triplet Triumph: IDH-Targeted Combo Shows High Remission in Tough-to-Treat AML. Summary:.For newly diagnosed, intensive….
0
6
0
RT @NicoGagelmann: Triple Threat: Revumenib Combo Delivers Powerful Punch in High-Risk AML published in @JCO_ASCO . Summary:.In older adult….
0
5
0
RT @DavidSteensma: With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial,….
0
81
0